J&J and Emergent wouldn’t give any details on the size of the batches that are usable, nor those being discarded.
The government agency based the decision on quality-control problems at the Emergent BioSolutions plant where the vaccine was made.
Reports that Emergent's CEO sold $10M of stock weeks before the announcement that his company had ruined 15 million J&J vaccine doses appear to show an egregious example of pandemic profiteering. I’m asking the SEC to investigate for insider trading.
Emergent took millions of dollars in taxpayer funds, made big promises, and then utterly failed in this crisis. This apparent profiteering is yet another example of the Trump administration's questionable contracting decisions that require extra scrutiny.
Officials with the firm, Emergent BioSolutions, claimed the mistake was an isolated incident, but our investigation found a pattern of lapses at the factory that suggests that the vaccine mix-up reflects deeper quality concerns.
"I have seen so many emergent intubations. I've seen people more sick than I've ever seen in my life." COVID ICU nurse Lacie Gooch hopes you will listen. @UNMC_ID @unmc @Prof_Lowe @DanielWJohnson9 @kcawcutt @JamesLawler11